Back to mobile site

H.C. Wainwright Reiterates Buy Rating on Janux Therapeutics (JANX)

April 22, 2026 6:42 AM EDT Send to a Friend
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $45.00 price target on Janux Therapeutics (NASDAQ: JANX).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login